Insulet Corporation (PODD) News Today: Latest Market and Industry Updates

137.23
2.7100
1.94 %
Daily range
Weekly range
  • Ciaran Ryan
  • 20 hours ago
Sanofi weighs Insmed takeover as rare disease deal review advances
Sanofi is assessing a possible acquisition of U.S. drugmaker Insmed as large pharmaceutical groups continue to look for growth through targeted biotech deals. The talks are still under review and ...
  • Andrey Mastykin
  • 23.09.2026
Insulet stock falls over 3% as chunk of selling follows credit agreement amendment and weaker guidance
Insulet Corporation (PODD) slid 3.02% today as weakness followed recent amendments to its credit agreement and softer forward guidance, with sellers continuing to dominate. This move is reinforced ...
  • Jainam Mehta
  • 30.07.2026
Insulet stock falls over 4% as class action lawsuits allege Omnipod manufacturing defects
Insulet Corporation (PODD) dropped 4.04% after class action lawsuits were announced over alleged manufacturing control defects involving its Omnipod insulin delivery systems. The move is supported ...
  • Ciaran Ryan
  • 16.07.2026
Insulet stock rises over 4% as class action lawsuits allege misleading product safety statements
Insulet Corporation (PODD) climbed 4.26% on renewed buying interest after multiple securities class action lawsuits were filed alleging misleading statements about product safety and manufacturing ...
  • Sholanke Dele
  • 30.06.2026
Insulet stock price forecast: $154.05 support as PODD consolidates
Insulet (PODD) stock is trading at $157.8 after a modest move lower for the day. The price remains above its key short- and medium-term moving averages but stays below ...